Back
Science

Implantable living material containing engineered bacteria shows long-term containment and infection treatment in mice

View source

Researchers have developed an implantable living material (ILM) that contains genetically engineered bacteria capable of sensing infections and releasing therapeutic molecules on demand while remaining physically separated from surrounding tissue.

The material remained intact for six months in laboratory testing with no detectable bacterial leakage.

Overview of the Innovation

A new class of implantable living material (ILM) represents a significant advance in the field of "living therapeutics." The ILM is built from bacteria-filled gelatin microgels, which are then embedded within a reinforced polyvinyl alcohol framework. The material's stiffness halts bacterial growth, preventing escape, while its toughness withstands mechanical stress from surrounding tissues.

Performance and Safety

In laboratory tests, the material showed no leakage for six months under conditions mimicking long-term physiological stress. This is a dramatic improvement over previous biomaterial systems, which confined microbes for only up to two weeks. The bacteria were engineered to detect chemical signals from Pseudomonas aeruginosa, a common cause of implant-related infections, and then self-destruct to release an antibacterial protein.

Real-World Application

In a mouse model of joint infection, the system reduced bacterial burden, demonstrating its potential for clinical use.

Background Context

Engineered living cells are being investigated as "living therapeutics" that can autonomously sense disease and deliver treatment at affected sites. Bacteria are attractive due to their programmability, but safety concerns require physical containment. Previous biomaterial systems confined microbes for only up to two weeks.

Expert Perspective

"Rather than treating the scaffold as a passive vehicle, Harimoto et al. treat it as an active determinant of whether contained bacteria can function safely over time. This reframing brings living therapeutics closer to a model in which long-term, in vivo embedded therapeutic function replaces repeated drug administration."

— Kaige Chen and Quanyin Hu, in a related Perspective